Amgen's 4th-qtr profit leaps 39%

US biotech major Amgen (Nasdaq: AMGN) late yesterday presented a strong set of financials, with fourth-quarter 2015 adjusted net income up 19% to $1.98 billion, or earnings per share of $2.61, up 21%, on revenues of $5.54 billion, an increase of 4%, in line with Wall Street expectations. Consensus analysts’ estimates were for EPS of just $2.29

On a GAAP (generally-accepted accounting principles) basis, net income rocketed 39% to $2.03, or $2.37 a share, up 41%. Amgen’s shares dipped 0.3% to $147.90 in after-hours trading on Thursday.

For the full year, total revenues increased 8% to $21.66 billion, with 8% product sales growth. Adjusted operating income grew 19% to $10.05 billion and adjusted EPS grew 19% to $10.38. GAAP net income grew 35% to $5.16 billion for the full year, with GAAP EPOS also up 35% at $6.70.